

A/D58140

10/240946

FORM PTO-1619A  
Expires 06/30/99  
OMB 0651-0027

PTO Rec'd PCT/PTO

03 OCT 2002

U.S. Department of Commerce  
Patent and Trademark Office  
**PATENT**

01-29-2003

AstraZeneca Docket No.  
100008-1P US

HEET

102344223

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

**Submission Type**

☒ New

☐ Resubmission (Non-Recordation)  
Document ID#

☐ Correction of PTO Error  
Reel #  Frame #

☐ Corrective Document  
Reel #  Frame #

**Conveyance Type**

☒ Assignment ☐ Security Agreement

☐ License ☐ Change of Name

☐ Merger ☐ Other

**U.S. Government**  
(For Use ONLY by U.S. Government Agencies)

☐ Departmental File ☐ Secret File

**Conveying Party(ies)**

☐ Mark if additional names of conveying parties attached

Execution Date  
Month Day Year  
08/21/2002

Name (line 1) Peter BERNSTEIN

Name (line 2)

**Second Party**

Name (line 1)

Name (line 2)

Execution Date  
Month Day Year**Receiving Party**

☐ Mark if additional names of receiving parties attached

Name (line 1) AstraZeneca AB

Name (line 2)

Address (line 1)

Address (line 2)

Address (line 3) S-151 85 Sodertalje

City

Sweden

State/Country

Zip Code

☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

**Domestic Representative Name and Address**

Enter for the first Receiving Party only.

Name Kenneth F. Mitchell

Address (line 1) AstraZeneca Pharmaceuticals

Address (line 2) Global Intellectual Property

Address (line 3) P.O. Box 15437

Address (line 4) Wilmington, Delaware 19850-5437

FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:  
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

**PATENT**  
**REEL: 013389 FRAME: 0102**

10/240946

PTO2 Rec'd PCT/PTO 03 OCT 2002

FORM PTO-1619B  
Expires 06/30/99  
OMB 0651-0027

Page 2

U.S. Department of Commerce  
Patent and Trademark Office  
**PATENT****Correspondent Name and Address**

Area Code and Telephone Number 302-886-3726

Name AstraZeneca Pharmaceuticals LP

Address (line 1) Global Intellectual Property

Address (line 2) 1800 Concord Pike

Address (line 3) P. O. Box 15437

Address (line 4) Wilmington, Delaware 19850-5437

**Pages**Enter the total number of pages of the attached conveyance document  
including any attachments.

# 1

**Application Number(s) or Patent Number(s)**☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)

Patent Number(s)


If this document is being filed together with a new Patent Application, enter the date the patent application was  
signed by the first named executing inventor.

Month Day Year

**Patent Cooperation Treaty (PCT)**

Enter PCT application number

only if a U.S. Application Number  
has not been assigned.

PCT SE01/00752

PCT

PCT

PCT

PCT

PCT

**Number of Properties**

Enter the total number of properties involved.

# 1

**Fee Amount**

Fee Amount for Properties Listed (37 CFR 3.41): \$ 40.00

Method of Payment:  
Deposit AccountEnclosed ☐ Deposit Account ☒

(Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number:


# 26-0166

Authorization to charge additional fees:

Yes ☒ No ☐**Statement and Signature**

*To the best of my knowledge and belief, the foregoing information is true and correct and any  
attached copy is a true copy of the original document. Charges to deposit account are authorized, as  
indicated herein.*

Kenneth F. Mitchell



Oct-3 '02

Name of Person Signing

Signature

Date

**PATENT**  
**REEL: 013389 FRAME: 0103**

PATENT APPLICATION

Docket No. (Optional)  
**100008-1P US**

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

**Peter BERNSTEIN**, of 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 USA

hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: **NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS** and which is found in

- (a) \_\_\_ U.S. patent application executed on even date herewith;
- (b) \_\_\_ U.S. patent application executed on \_\_\_\_\_;
- (c) \_\_\_ U.S. application serial no. \_\_\_\_\_ filed on \_\_\_\_\_
- (d) X International application no. **PCT/SE01/00752** filed on **5 April 2001**


and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;


ASSIGNOR(S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;


ASSIGNOR(S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this

21<sup>st</sup> day of August, 2002

  
**Peter BERNSTEIN**

WITNESS:   
DATE: Aug 21 '02

WITNESS:   
DATE: August 21, 2002

☐ Additional page(s) are attached hereto.